Revive Therapeutics announces research collaboration with North Carolina State University to develop a novel biosynthetic version of psilocybin

Revive Therapeutics announces research collaboration with North Carolina State University to develop a novel biosynthetic version of psilocybin

Revive Therapeutics Ltd (CSE:RVV) (OTCMKTS:RVVTF) (FRA:31R) announced Thursday that it has entered into a sponsored research and an exclusive option-to-license agreement with North Carolina State University to develop a novel biosynthetic version of psilocybin.    It is based on a natural biosynthesis enzymatic platform developed by NC State professor and researcher Dr Gavin Williams and provides a potentially simple and efficient method for rapidly producing natural products — such as psilocybin — using an engineered enzymatic pathway in E. coli.  Revive said it is seeking to develop and commercialize its own pharmaceutical-grade psilocybin with this biosynthesis technology at scale to support the company’s current psilocybin-based product pipeline that includes an oral thin film product currently being developed in collaboration with the University of Wisconsin-Madison and the intellectual property and research with psilocybin being developed by PharmaTher Inc (CSE:PHRM) (OTCQB:PHRRF).  READ: Revive Therapeutics Ltd set to hit enrollment goals for Phase 3 coronavirus trial of Bucillamine “We are excited to partner with NC State and work with Dr. Williams and his team to develop a proprietary form of psilocybin that can be produced at scale for research and commercial purposes while allowing us to create our own unique product offerings with psilocybin in different delivery methods so as to treat the various mental health conditions and other diseases that psilocybin has shown to be a potential viable treatment option for,” said Revive CEO Michael Frank in a statement. “We continue to expand our psychedelic pharmaceutical objectives in specializing in novel products and uses of psilocybin for unmet medical needs.” Revive said that Dr Williams and his team recently developed an artificial enzymatic platform called the ‘Alcohol Dependent Hemiterpene’ (ADH) pathway for the construction of alkyl pyrophosphates. The products of the ADH pathway will be used to generate key building blocks for psilocybin and its derivatives. The goal is to engineer E. coli to be a factory for psilocybin production, using a completely artificial biosynthetic logic. The Ontario-based company noted that Dr Williams is a decorated chemist and is well-known for his innovative work in polyketide biosynthesis, the development of enzymatic tools for protein engineering, and the development of novel biosensors to guide metabolic engineering and high-throughput synthetic biology.  His research lab has an interest in combining the power of biology and organic chemistry to provide access to new complex organic molecules. More specifically, Williams Lab leverages enzyme engineering, biocatalysis, metabolic engineering, organic chemistry, and synthetic biology to access and diversify the structures of natural products, which forms an innovative and powerful platform for drug development and discovery. Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham  

Post a Comment